 Invest. 1994. 93:776-787.)
The development of late bronchial responses after airway challenge may be the initial physiologic sign ofa chronic inflammatory process that leads to a prolonged increase in airway responsiveness. A number ofrecent studies ofasthmatics have characterized the inflammatory patterns associated with the development of late responses and airway hyperresponsiveness after airway antigen challenge (1) (2) (3) (4) . Like bronchoalveolar lavage fluids (5) , biopsied airway tissues (6-10) from patients with asthma contain increased numbers of eosinophils and T lymphocytes. Moreover, eosinophils and lymphocytes recruited into airway tissues after antigen challenge exhibit characteristics compatible with their activation.
One recognized adherence pathway that eosinophils and T lymphocytes might utilize in common is binding to vascular cell adhesion molecule-1 (VCAM-1)1 that can be induced to be expressed on endothelial cells ( 1 1). Cell binding to VCAM-1 is mediated by very late antigen-4 (VLA-4), the a4f3 heterodimeric integrin (CD49d/CD29) expressed on both T lymphocytes and eosinophils, but not neutrophils (12) (13) (14) (15) (16) . VLA-4 also mediates binding of these cells to the CS-1 region of fibronectin ( 17) and potentially to an additional endothelial cell ligand ( 18) . Blockade of the a4 chain, CD49d, with specific monoclonal antibodies can inhibit adherence of eosinophils, lymphocytes, and monocytes to VCAM-1 and fibronectin ( 12, 13, 16, (19) (20) (21) . Another a4-containing heterodimeric integrin, a437, mediates adherence of T lymphocytes to Peyer's patches (22) , and anti-CD49d antibodies can block cellular adhesion mediated by the a437-integrin (23) . In addition to participation of a4-integrins in cellular adhesion, engagement of a4-integrins may be involved in cellular activation pathways (24) (25) (26) (27) (28) . Thus, a4-integrins are potentially involved by varied mechanisms in pathways of recruitment and activation of lymphocytes and eosinophils.
To formally evaluate whether inhibition of a4-integrin functions might have a beneficial effect in allergic diseases in vivo, we have utilized an a4-specific monoclonal antibody, HP 1 / 2, that blocks and does not promote a4-integrin-dependent cellular adhesion and activation ( 19, 28) . If sponsiveness that normally persists for 2 wk after antigen challenge.
Methods

In vitro studies
Detection ofa4 expression on sheep leukocytes. The ability of mAb HP 1/2 against human a4 ( 19, 28) to detect and inhibit sheep a4-integrins was evaluated by flow cytometry, radioimmunoprecipitation, and leukocyte adhesion assays. Sheep venous blood anticoagulated with EDTA was diluted 1:1 with Dulbecco's PBS without calcium and magnesium (Sigma Chemical Co., St. Louis, MO) and fractionated by sedimentation on Ficoll-Hypaque (Pharmacia, Inc., Piscataway, NJ) gradients. Mononuclear leukocyte layers and granulocyte pellets (eosinophils and neutrophils) were collected. Eosinophils were separated from neutrophils by Percoll sedimentation at a density of 1.085. Leukocytes were stained with HP 1/2 (29) or an IgG, isotype control myeloma protein (MOPC 21, Organon-Technika, West Chester, PA) and after incubation with phycoerythrin-labeled goat F(ab')2 anti-mouse IgG were analyzed by flow cytometry as previously described (12) . Flow cytometry was performed on a FACStar Plus and analyzed by the program Consort 30 (Becton Dickinson & Co., Fairleigh, NJ). Because eosinophils exhibit greater green autofluorescence than do neutrophils or mononuclear leukocytes, dual-parameter flow cytometry was utilized with cellular autofluorescence analyzed with a 530-nm filter in the green detector channel and phycoerythrin staining evaluated with a 575-nm filter in the second channel. Leukocytes, in various preparations depleted of neutrophils, eosinophils or mononuclear cells, were gated by forward and orthogonal light scatter and 10,000 gated cells were analyzed.
For cell surface labeling and immunoprecipitation of the a4-integrin subunit, sheep and control human blood mononuclear leukocytes were labeled for 30 min at 40C with 1 mCi of Na 1251 (Du Pont-New England Nuclear, Boston, MA) using Enzymobead solid phase radioiodination reagent (Bio-Rad Laboratories, Richmond, CA) and lysed in the presence of 1% Triton X-100, 1 mM MgCI2, 8 mM iodoacetamide, 1 mM PMSF in PBS for I h at 4°C. Lysates were clarified by centrifugation at 10,000 rpm for 10 min, precleared with 4 Ml ofnormal rabbit serum, and 10 ,ug/ 106 cells of purified mouse myeloma MOPC 21 IgG, protein overnight at 4°C, followed by 200 ,l of recombinant protein G agarose (Gibco BRL, Gaithersburg, MD) and centrifuged to remove the insoluble complexes. Precleared lysate containing 107 cell equivalents were then immunoprecipitated with 2 ML of rabbit a4 COOH terminus-specific antisera: anti-a4, N 1 1, gift of Dr. Martin E.
Hemler (Dana Farber Cancer Institute, Boston, MA) (30), 10Ag! 106 cell equivalents of HP 1/2, 2 Mul of normal rabbit serum, or 10 Mg/ 106 cell equivalents of MOPC 21, followed by 100 Ml of protein G agarose. The immunoprecipitates were washed five times with 1 ml of 0.1% Triton X-100 PBS, eluted with sample buffer (5% glycerol, 1.5% SDS, 3 M Tris, pH 6.8), and analyzed without reduction by SDS/PAGE utilizing 7% polyacrylamide gels. The gels were stained with Coomassie brilliant blue and autoradiographed utilizing Kodak XAR-5 film.
Adhesion assays on recombinant soluble (rs) VCAM-1 coated plates were performed as follows: rsVCAM-1 purified from CHO cellconditioned medium by immunoaffinity chromatography exactly as previously described (31 ) was added from a 1 mg/ml stock solution to 100 Ml binding buffer ( 15 mM sodium bicarbonate/35 mM sodium carbonate, pH 9.2) in individual wells of a 96-well bacteriologic plastic plate (Linbro/Titertek, Hamden, CT), and incubated overnight at 4°C. Plates were blocked with 1% BSA in PBS for 1 h at room temperature, washed once with RPMI 1640 containing 10% FBS (RPMI/ 10), and adhesion assays with sheep peripheral blood mononuclear leukocytes were performed with inverted centrifugation as described ( 11, 32) . Blood leukocyte adhesion was quantified by fluorescence as described (33 (36) (37) (38) . Pleural pressure was estimated with the esophageal balloon catheter (filled with I ml of air), which was positioned 5-10 cm from the gastroesophageal junction. In this position the end expiratory pleural pressure ranged between -2 and -5 cmH2O. Once the balloon was placed, it was secured so that it remained in the same position for the duration of the experiment. Lateral Aerosol delivery systems. All aerosols were generated using a disposable medical nebulizer (Raindrop, Puritan Bennett, Lenexa, KS) that provided an aerosol with a mass median aerodynamic diameter of 3.2
Am as determined by a cascade impactor (Andersen Instruments, Inc., Atlanta, GA). The nebulizer was connected to a dosimeter system, consisting of a solenoid valve and a source of compressed air (20 psi). The output ofthe nebulizer was directed into a plastic T-piece, one end ofwhich was connected to the inspiratory port ofa respirator (Harvard Apparatus, S. Natick, MA). The solenoid valve was activated for one second at the beginning ofthe inspiratory cycle ofthe respirator. Aerosols were delivered at a tidal volume of 500 ml and a rate of 20 breaths per minute as previously described (36, 38) .
Concentration response curves to carbachol aerosol. To assess bronchial responsiveness, we performed cumulative concentration response curves to carbachol by measuring SRL immediately after inhalation of buffer and after each consecutive administration of 10 breaths of increasing concentrations of carbachol (0.25, 0.5, 1.0, 2.0, and 4.0% wt/ vol buffered saline). The provocation test was discontinued when SRL increased over 400% from the post-saline value or after the highest carbachol concentration had been administered. Bronchial responsiveness was assessed as previously described (36, 37) by determining the cumulative carbachol concentration (in breath units [BUI) that increased SRL by 400% over the post-saline value (PC4w) by interpolation from the dose response curve. One BU was defined as one breath of a 1% wt/vol carbachol aerosol solution.
Bronchoalveolar lavage (BAL). The distal tip of a specially designed 80-cm fiberoptic bronchoscope was wedged into a randomly selected subsegmental bronchus. Lung lavage was performed by slow infusion and gentle aspiration of 3 X 30-ml aliquots of PBS (pH 7.4) at 39°C, using 30-ml syringes attached to the working channel of the bronchoscope (38) . The effluent collected was strained through gauze to remove mucus and then centrifuged at 420 g for 15 min. The cell pellet was resuspended in buffered saline, and an aliquot of this resuspension was transferred to a hemocytometer chamber to determine total cells. Total viable cells were assessed by trypan blue exclusion. A second aliquot of the cell suspension was spun in a cytospin (600 rpm for 10 min) and stained by Wright-Giemsa to identify cell populations. given an intravenous infusion of 1 mg/kg HP 1/2 or an equivalent volume ofsaline. 30 min after treatment, SRL was remeasured and then the animals were challenged with antigen. SRL was remeasured immediately after, hourly from 1 to 6 h after and half-hourly from 6.5 to 8 h after antigen challenge as previously described (35, 38) . Postchallenge determinations of airway responsiveness (PC4w) were made at 24 and 48 h, and 1 and 2 wk after antigen challenge. For these studies peripheral blood was drawn for differential analysis and determination of serum levels of HP 1/2 at baseline, 30 min post drug, 1, 2, 3, 4, 6, 8, 24, and 48 h, and 1 and 2 wk after antigen challenge. Postchallenge BAL was performed 4, 8, 24 , and 48 h, and 1 and 2 wk after challenge. These studies were carried out in eight sheep in a randomized crossover fashion. Control and drug trials were separated by at least 3 wk. Our previous studies had shown that this time interval was sufficient for the sheep to recover from prior challenges (41 ) . Consistent with these previous studies, there were no differences in baseline pulmonary function (see Results) or baseline BAL (see Table I ).
A similar protocol was used for a group of five sheep challenged with the nonspecific isotypic mAb 1E6, except that the post challenge measurements of PC4w and peripheral blood differentials were stopped at 48 h after challenge. BAL was not performed in this series.
In a third protocol, the effect of giving HP 1/2 after antigen challenge was assessed. In five sheep, PC~w was measured within 5 d of antigen challenge. On the challenge day, SRL was measured before, immediately after, and 1 and 2 h after antigen challenge. Then the sheep were given HP 1/2 (1 mg/kg, i.v.) or saline. For these posttreatment studies, the saline trials were done before the drug trials. Measurements of SRL were continued from 3 through 8 h as previously described. PC4w was measured 24 and 48 h after antigen challenge.
Aerosol treatment studies. Baseline airway responsiveness was determined as described above. On the challenge day, baseline SRL was measured and then the sheep were given 16 mg HP 1/2 (n = 5 ) or 1E6 (n = 4) by aerosol. Thirty minutes after drug treatment, SRL was measured and then the sheep were challenged with antigen. Post challenge determinations of PC4w and peripheral bloods were obtained through 48 h as described above.
Comparison of intravenous and aerosol doses. Based on calculations by Kim et al. (42) , -15% of all aerosol generated is lost in the endotracheal tube. Ofthe remaining aerosol, -40% is deposited in the lung, using this study's coordinated nebulizer-delivery system and breathing pattern. Based on these predictions, the calculated drug dose actually reaching the lung for the aerosol trial would be 5. 4 (Fig. 2) . Moreover, an anti-: mAb, TS 2/16, that enhances VLA-4-mediated adherence (34), enhanced sheep leukocyte to VCAM-1, as it did control RAMOS cells (Fig. 2) . Thus, HP 1/2 binds to an adhesion blocking epitope on sheep a4-integrins and VLA-4, a431, participates in sheep leukocyte adherence to VCAM-1.
Intravenous treatment studies (pretreatment) Bioavailability of HP 1/2. After the intravenous administration of 1 mg/kg of HP 1/2, plasma concentrations (Fig. 3) reached steady-state levels with 30 min after injection (22.1±3.1 ,ug/ml) and remained constant for up to 48 h. The HP 1/2 concentrations decreased to 2.6±1.3 ,ug/ml by 1 wk and only two of the eight sheep showed detectable HP 1/2 by 2 wk. In two sheep treated with 0.2 mg/kg HP 1/2, plasma concentrations of HP I/2 were 12.3±1.8, 2.5±2.5, and < 1 ,ug/ml at 2 min, 30 min, and 48 h after injection.
Airway responses. Fig. 4 shows the time course of the airway responses before and after antigen challenge when the animals were given 1 mg/kg HP 1/2 intravenously. In the control trial, SRL increased 380±42% (P < 0.05) from a baseline value of 0.99±0.03 liter X cm2O/liters per s immediately after challenge. SRL returned to baseline values by 4 h postchallenge, but then began to increase again by 5 h postchallenge. The maximum increase during this late response (i.e., 5-8 h) was 175±16% (P < 0.05). Treatment with HP 1/2 had no effect on baseline tone. HP 1/2 provided no protection against the immediate bronchoconstrictor response to inhaled antigen, with SRL increasing 345±33% (P < 0.05) from a baseline value of 0.99±0.04 liter X cm H20/liters per s. SRL remained significantly elevated above baseline 1 h after challenge, but then, returned to prechallenge values and did not increase significantly above baseline throughout the remainder ofthe 8 h. The maximum increase in SRL during the late response was 44±11% (P < 0.05 vs. control). Thus, HP 1/2 at 1.0 mg/kg provided a mean 75% protection against the late-phase response in these animals. The effect of HP 1 / 2 was dose dependent; reducing the dose to 0.2 mg/kg was not sufficient to protect against the late response. In two sheep treated with 0.2 mg/kg HP 1/2, the peak late response was 209±59% compared to 134±3% in the control trial.
To ensure that the protective effect of HP (Fig. 4) Values are mean±SE for 13 control sheep and 8 HP 1/2-treated sheep. * P < 0.05 vs. baseline; * P < 0.05 vs. control.
Intravenous treatment studies (postchallenge treatment)
Postchallenge treatment with intravenous HP 1 / 2 was also effective in blocking the late airway response and the post antigen-induced airway hyperresponsiveness (Fig. 7) . The changes in SRL were the same in the control and HP 1/2 trials before and for 4 h after antigen challenge. By 5 h, however, SRL began to increase in the control trial, but not in the HP 1/2 trial. The peak late response in the control trial was 177±17% compared to 33±7%, when the animals were treated with HP 1/2 (P <0.05). Posttreatment with HP 1/2 was also effective in blocking the post-antigen-induced airway hyperresponsiveness over 48 h (P < 0.05).
Aerosol treatment Airway responses. Fig. 8 shows that treating sheep with HP 1/2 aerosol ( 16 mg total dose) 30 min before antigen challenge was also effective in blocking the late response and airway hyperresponsiveness. The protective effect was specific for HP 1/2 because the same dose of 1E6 had no protective effect. Fig. 9 shows that the differences in the physiological responses between aerosol HP 1/2 and 1E6 were not the result of differences in total WBC or differential counts between the groups. Total WBC and differential in both the HP 1/2 and 1E6 groups showed a pattern ofresponses similar to that seen in the intravenous trial. This protection afforded by aerosol HP 1/2 occuffed in the absence of detectable serum levels of the mAb. None ofthe serum samples obtained from the five sheep at the times where mAb was most likely to be present, i.e., 30 min after drug treatment, immediately after antigen challenge and 1 h after antigen challenge contained detectable mAb.
Airway responsiveness. In the HP 1/2-treated sheep PC4w
was not significantly changed 24 or 48 h after challenge from the prechallenge value. Prechallenge PC4w was 20.3±0.6 BU whereas after antigen challenge BU were 16.0±2.3 and 27.1±1.64 for 24 and 48 h, respectively (P = NS). In the 1E6
sheep, PC4w fell significantly (P < 0.05) 24 and 48 h after antigen challenge, respectively, from a baseline value of 23.7±5.6 to 11.6±2.7 and 8.4±2.9 BU (Fig. 8 ).
Effect ofHP 1/2 on EPO activity. Although the in vivo data provide some support that HP 1/2 can slow eosinophil recruitment to the airway, it is possible that binding of HP 1/2 to the a4-integrin can modulate cell function as well. To test this possibility, sheep eosinophils were stimulated with PAF ( l0 -M) in the presence and absence of HP 1 / 2 and EPO production was measured as an index of cell activation. In the control cells, PAF caused a 3.5±0.9 (n = 6)-fold increase in EPO production, which was significantly greater than the 1.9±0.1-fold increase observed in the HP 1/2-treated cells. HP 1/2 had no effect on unstimulated eosinophils ( 1. 1±0. 1, n = 4).
Discussion
The results ofthis study indicate that a blocking mAb to a4-integrins, HP (45) . Conversely, the role of the neutrophil in these pathophysiologic events is less convincing. Unlike eosinophils, recovery of neutrophils in BAL and in biopsy specimens is sporadic and, in contrast to eosinophils obtained from BAL, markers of neutrophil activation have not been correlated with asthma symptoms (46) . That the eosinophil may be more prominent in mediating the late response and airway hyperresponsiveness is not surprising considering the differences in the biochemical pathways of the two cell types. The neutrophil does not produce sulfidopeptide leukotrienes (47, 48) , i.e., leukotrienes C4, D4, and E4) major mediators ofthe late response (38, (49) (50) (51) ), whereas the eosinophil, is a potent source of these spasmogens. In addition, eosinophils release major basic protein which damages respiratory epithelium (52, 53) and can provoke airway hyperresponsiveness (54, 55 Previous studies in Ascaris suum-sensitive monkeys suggest that selective endothelial adhesion proteins regulate specific pathophysiological events that follow antigen challenge. In an acute challenge model, an anti-human E-selectin mAb (CL2, 2 mg/kg, i.v.) was found to block the late bronchial response (56) . This protection was associated with a reduction in leukocyte, specifically in neutrophil, infiltration into the lung. No protection against the late bronchial response or the cellular influx was observed when the animals were treated with an anti-intracellular adhesion molecule-l mAb (R6.5, 2 mg/kg, i.v.), a mAb that when used in a chronic challenge model had been shown to prevent the eosinophilic inflammatory response and the development of airway hyperresponsiveness (57). The conclusion from these studies was that E-selectin modulates the acute airway neutrophilic inflammation that is characterized by a late bronchial obstruction, and that intracellular adhesion molecule- 1 %.O25-lymphocyte-derived cytokines, such as interleukin 5, are involved in eosinophil activation in the airways ( 11 ) . Preventing eosinophil activation could inhibit the release ofsulfidopeptide leukotrienes, modulators of late phase airway responses (38, 50) , and eosinophil granular proteins that can contribute to airway hyperresponsiveness (54, 55) . Recent observations by Wardlaw and colleagues showed that VLA-4 dependent adhesion of eosinophils to fibronectin resulted in short-term priming of eosinophils for calcium dependent leukotriene release (60) . Likewise, Neeley et al. (61 ) found that VLA-4 mediated interaction with fibronectin results in increased FMLP-induced degranulation of peripheral blood eosinophils. These findings are consistent with our own studies showing inhibition of EPO activity in PAF-stimulated eosinophils treated with HP 1/2 which indicate that a4 antibodies can down-regulate eosinophil function directly. Such a mechanism might explain why biopsies taken from individuals with the most responsive airways had greater numbers of VLA4-positive staining cells (62) .
In conclusion, these results support a role for a4-integrins in the production of asthmatic late phase airway obstruction and hyperresponsiveness. Inhibition ofairway hyperresponsiveness was persistent for over 2 wk after systemic administration of the anti-a4 blocking antibody. Moreover, administration of the anti-a4 antibody into the airway was effective indicating the potential utility of inhalational approaches to mediating airway cell activation that contributes to asthma pathophysiology.
